Search Results

Soligenix, Inc. encourages its eligible stockholders to vote “FOR” a Reverse Stock Split.

Soligenix, Inc. announced that the Company will deliver a corporate presentation at the upcoming conferences below.

Soligenix, Inc. announced today that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 16 pre-split shares.

Soligenix, Inc. announced today positive clinical results from a comparability study evaluating HyBryte™ (synthetic hypericin) versus Valchlor® (mechlorethamine gel) in the treatment of cutaneous T-cell lymphoma (CTCL).

PRISM MarketView, a leader within the financial markets and news community, announces the release of an article highlighting Soligenix Inc’s (Nasdaq: SNGX) key achievements and pathway to regulatory success through its lead product candidate, HyBryte™ (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma, a rare and chronic cancer.

Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced its recent accomplishments and financial results for the quarter ended March 31, 2024.

Soligenix, Inc. today that the Company will deliver a corporate presentation at The Microcap Conference.

Soligenix, Inc. announced today its recent accomplishments and financial results for the year ended December 31, 2023.

Soligenix, Inc. announced that it has received notice of intent to grant additional patents based on its patent application titled “Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines” in the United Kingdom and South Africa, with other international jurisdictions pending.

Soligenix, Inc. announced the pricing of its public offering of 11,875,000 shares of common stock and warrants to purchase up to 11,875,000 shares of common stock at a combined public offering price of $0.40 per share and accompanying warrant for aggregate gross proceeds of approximately $4.75 million, before deducting placement agent fees and other offering expenses.